UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 orOR 15(d) of ~~the~~The ~~Securities Exchange Act of 1934~~

~~Date~~Securities ofExchange ~~Report~~Act ~~(Date~~ of 1934 ~~earliest event reported): May 16, 2011~~

Date of Report (Date of earliest event reported): June 27, 2011

ORTHOVITA, INC.

(Exact ~~Name~~name of ~~Registrant~~registrant as Specified in its Charter)

Pennsylvania	0-24517	23-2694857
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
77 Great Valley Parkway Malvern, Pennsylvania		19355
(Address of principal executive offices)		(Zip Code)

77 Great Valley Parkway Malvern, Pennsylvania		19355
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (610) 640-1775

(Former ~~Name~~name or ~~Former~~former ~~Address~~address, if ~~Changed~~changed ~~Since~~since ~~Last~~last ~~Report~~report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item 1.01~~Introduction ~~Entry~~and ~~into~~Background ~~a Material Definitive Agreement.~~

As previously reported, on May 16, 2011, Orthovita, Inc., a Pennsylvania corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Stryker Corporation, a Michigan corporation (“Parent”), and Owl Acquisition Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of Parent (“Purchaser”). Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, Purchaser commenced a tender offer (the “Offer”) on May 27, 2011, to acquire all of the outstanding shares of common stock of the Company, $0.01 par value per share (the “Shares”), at a purchase price of $3.85 per Share, net to the seller in cash, without interest thereon and less any applicable withholding taxes (the “Offer Price”).

On ~~May~~June 1627, 2011, ~~Orthovita,~~Parent ~~Inc.~~announced ~~(“Orthovita”)~~the ~~entered~~expiration ~~into an Agreement and Plan~~ of ~~Merger (~~the ~~“Merger~~offering ~~Agreement”)~~period, ~~with~~which ~~Stryker~~expired ~~Corporation,~~at a12:00 ~~Michigan corporation (“Parent”)~~midnight, ~~and~~New ~~Owl~~York ~~Acquisition~~City ~~Corporation~~time, aat ~~Delaware~~the ~~corporation~~end ~~and~~of anFriday, ~~indirect~~June 24, ~~wholly-owned~~2011 ~~subsidiary of Parent~~ (the “~~Purchaser~~Offering Period”).

~~Pursuant~~On June 27, 2011, at 11:59 p.m., Eastern Daylight Time, Purchaser was merged with and into the Company (the “Merger”) pursuant to the terms of the Merger Agreement, ~~upon~~with the ~~terms~~Company ~~and~~surviving ~~subject~~as an indirect wholly-owned subsidiary of Parent. The time of the Merger is referred to in this report as the ~~terms~~“Effective ~~thereof:~~Time.”

•Item ~~Purchaser~~1.02 ~~has~~Termination ~~agreed to commence a tender offer (the “Offer”), subject to certain conditions, no later than May 31, 2011, to purchase all the outstanding shares~~ of ~~Orthovita common stock (“Shares”) at~~ a ~~purchase~~Material ~~price~~Definitive ~~of $3~~Agreement.~~85 per share in cash (the “Offer Price”); and~~

•On asJune 28, ~~soon~~2011, asin ~~practicable~~connection ~~after~~with the ~~consummation~~closing of the ~~Offer~~Merger, ~~and~~the ~~satisfaction~~Company orreceived ~~waiver~~a ofpayoff ~~certain~~letter ~~conditions~~(the ~~set~~“Payoff ~~forth~~Letter”) infrom ~~the~~LB ~~Merger~~I ~~Agreement~~Group Inc., ~~Purchaser~~a ~~will~~Delaware ~~merge~~corporation ~~with~~(“LB I”), pertaining to the Company’s outstanding loans and ~~into~~related ~~Orthovita~~obligations evidenced by the Senior Secured Note and Warrant Purchase Agreement, dated July 30, 2007 (the “~~Merger~~Note Purchase Agreement”), by and ~~Orthovita~~between ~~will~~the ~~become~~Company anand ~~indirect~~LB ~~wholly-owned~~I and ~~subsidiary~~the ofrelated ~~Parent.~~agreements, Ininstruments and other documents entered into by the ~~Merger,~~Company ~~each~~or ~~Share~~its ~~remaining~~affiliates ~~outstanding~~with ~~following~~or for the ~~consummation~~benefit of LB I (together with the ~~Offer~~Note Purchase Agreement, ~~other~~the ~~than~~“Loan ~~Shares~~Agreements”), ~~held~~including, bywithout ~~Orthovita~~limitation, the or10% ~~Parent~~Senior orSecured ~~their~~Note ~~respective~~due ~~subsidiaries~~July 30, or2012, dated July 30, 2007, made by ~~shareholders~~the ~~who~~Company ~~have~~in ~~properly~~favor ~~exercised~~of ~~their~~LB ~~appraisal~~I. ~~rights~~Pursuant ~~under~~to ~~Pennsylvania~~the ~~law~~Payoff Letter, ~~will~~all beamounts ~~converted~~outstanding ~~into~~under the ~~right~~Loan toAgreements ~~receive~~(totaling ~~cash~~an aggregate of $37,498,611 (including approximately $1,633,333 in anearly ~~amount~~termination ~~equal~~fees)) towere repaid, the ~~Offer~~Loan ~~Price~~Agreements were terminated and LB I released and terminated all security interests and pledges securing the Company’s and its affiliates’ obligations under the Loan Agreements.

~~The~~Item ~~consummation~~3.01 Notice of ~~the~~Delisting ~~Offer~~or isFailure ~~subject~~ to ~~several~~Satisfy ~~closing conditions, including (i) that~~ a ~~majority~~ ofContinued ~~the~~Listing ~~outstanding~~Rule ~~shares of Orthovita common stock (determined on a fully diluted basis) be validly tendered and not withdrawn prior to the expiration of the Offer, (ii) the expiration~~ or ~~termination~~Standard; ofTransfer ~~any waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act~~ of ~~1976, as amended, (iii) the absence of a material adverse effect on Orthovita and (iv) certain other customary conditions~~Listing. ~~Neither the Offer nor the Merger is subject to any financing condition.~~

~~The~~As ~~parties~~a toresult of the ~~Merger~~consummation ~~Agreement~~of ~~have~~the ~~agreed~~Merger ~~that~~and ifrelated transactions, ~~following~~the ~~completion~~Company ofno longer fulfills the ~~Offer,~~ ~~Parent,~~requirements ~~Purchaser~~for ~~and~~continued listing ~~any~~on ~~other~~the ~~subsidiary~~NASDAQ ofGlobal ~~Parent~~Market ~~collectively~~(“NASDAQ”) ~~own~~pursuant atto ~~least~~NASDAQ ~~80%~~Marketplace ofRule ~~the~~5450. ~~Shares~~Accordingly, ~~the~~on ~~Merger~~June 27, ~~will~~2011, bethe ~~completed~~Company ~~without~~requested athat ~~meeting~~NASDAQ offile ~~Orthovita’s~~with ~~shareholders~~the ~~pursuant~~Securities toand ~~Pennsylvania’s~~Exchange Commission (“~~short-form~~SEC”) ~~merger~~a ~~statute.~~Notification Ifof ~~Parent,~~Removal ~~Purchaser~~from Listing and/or ~~any~~Registration ~~other~~under ~~subsidiary~~Section 12(b) of ~~Parent~~the ~~collectively~~Securities ~~own~~Exchange ~~less~~Act ~~than~~of ~~80%~~1934, ofas ~~the~~amended, ~~Shares~~on ~~following~~Form 25, ~~completion~~thereby ofeffecting the ~~Offer,~~delisting ~~Orthovita~~of ~~will~~the ~~hold~~Shares afrom ~~special~~NASDAQ. ~~meeting~~On ofJune 27, ~~shareholders~~2011, toNASDAQ ~~obtain~~filed ~~shareholder~~the Form ~~approval~~25 ofwith the ~~Merger~~SEC.

Orthovita has agreed to customary covenants governing the conduct of its business, including the operation of its business in the ordinary course until (i) the date following consummation of the Offer on which a majority of Orthovita’s directors consists of designees of Purchaser or (ii) the date on which the Merger Agreement is terminated in accordance with its

~~terms.~~Item Orthovita has agreed not to solicit or initiate discussions with third parties regarding other proposals to acquire Orthovita and to certain restrictions on its ability to respond to any such proposal, subject to fulfillment of certain fiduciary requirements of Orthovita’s board of directors3.03 ~~The~~Material ~~Merger~~Modification Agreement also includes customary termination provisions for both Orthovita and Parent and provides that, in connection with the termination of the Merger Agreement under specified circumstances, Orthovita will be required to ~~pay~~Rights ~~Parent a termination fee~~ of ~~$9,891,604.~~Security Holders.

~~Upon~~On ~~completion~~June 27, ~~of the Offer~~2011, ~~pursuant~~at tothe ~~their~~Effective ~~respective terms~~Time, ~~all of Orthovita’s outstanding options to purchase Orthovita common stock and~~ each ~~share~~Share ofissued ~~restricted stock will vest~~ and ~~become exercisable.~~outstanding ~~Upon~~as ~~consummation~~ of ~~the~~immediately ~~Merger,~~prior ~~each option~~ to ~~purchase~~the ~~Orthovita~~Effective ~~common~~Time ~~stock~~(excluding ~~that~~Shares isheld ~~outstanding~~by ~~will~~the ~~be surrendered~~Company, ~~and~~any ~~the~~wholly ~~holder~~owned ofsubsidiary ~~each such option will be entitled to receive an amount in cash equal to the excess~~ of the ~~Offer~~ ~~Price~~Company, ~~over~~Parent ~~the~~or ~~exercise~~Purchaser ~~price~~and ~~per~~Shares ~~share~~held ofby ~~such option, if~~ any, ~~multiplied~~shareholder bywho ~~the~~properly ~~total~~demands ~~number~~appraisal of ~~shares subject to such option. In addition~~his, ~~upon~~her ~~the~~or ~~consummation~~its ofShares) ~~the~~was ~~Merger,~~cancelled ~~each~~and ~~share of restricted stock will be~~ converted into the right to receive ~~a cash payment equal to~~ the Offer Price.

~~In addition, also on May~~Section ~~16,~~5—Corporate ~~2011,~~Governance Orthovita entered into the Amendment No. 1 to Warrant (the “Warrant Amendment”) with LB I Group, Inc. (“LB I Group”), amending the Warrant, dated as of July 30, 2007 (the “Warrant”), entitling LB I Group, as the holder of the Warrant to purchase 1,100,000 shares of Orthovita common stock at the price of $3.41 per share. Pursuant to the terms of the Warrant Amendment, upon consummation of the Merger, the Warrant, to the extent not previously exercised, will entitle the holder thereof to receive an amount in cash equal to the excess of the Offer Price over the exercise price per share of the Warrant, multiplied by the total number of shares subject to the Warrant. The foregoing description of the Warrant Amendment does not purport to be complete and isManagement ~~qualified in its entirety by reference to the full text of the form of Warrant Amendment, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.~~

~~The~~Item ~~summary~~5.01 ofChanges ~~the principal terms of the Merger Agreement~~ in ~~this~~Control ~~report and the copy~~ of the Merger Agreement filed as an exhibit to this report are intended to provide information regarding the terms of the Merger Agreement and are not intended to modify or supplement any factual disclosures about Orthovita in its public reports filed with the Securities and Exchange Commission (“SEC”)Registrant. ~~In particular, the Merger Agreement and related summary are not intended to be, and should not be relied upon as, disclosures regarding any facts and circumstances relating to Orthovita.~~

~~The~~Parent ~~Merger~~and ~~Agreement~~Purchaser ~~includes~~have ~~customary~~advised ~~representations~~the Company that, ~~warranties~~based ~~and~~on ~~covenants~~information offrom ~~Orthovita,~~American ~~Parent~~Stock Transfer and ~~Purchaser~~Trust ~~made~~Company, ~~solely~~LLC, the depositary for the ~~benefit~~ Offer, as of the ~~parties~~expiration toof the ~~Merger~~Offering ~~Agreement.~~Period ~~The~~at 12:00 ~~assertions~~Midnight, ~~embodied~~New inYork ~~those~~City ~~representations~~time, ~~and~~at ~~warranties~~the ~~were~~end ~~made~~of ~~solely~~Friday, ~~for~~June 24, ~~purposes~~2011, ofan ~~the~~aggregate ~~contract~~of ~~among Orthovita~~67,512,965 ~~Purchaser~~Shares ~~and~~(including ~~Parent~~approximately ~~and~~1,312,608 ~~may~~Shares be subject to ~~important~~guarantees ~~qualifications~~of ~~and limitations~~delivery) ~~agreed~~were tovalidly tendered by Orthovita,’s ~~Purchaser~~shareholders and not ~~Parent~~withdrawn, inrepresenting ~~connection~~approximately ~~with~~87.6% of the ~~negotiated~~total ~~terms~~outstanding Shares. ~~Moreover,~~All ~~some~~Shares ofthat ~~those~~were ~~representations~~validly tendered and ~~warranties~~not ~~may~~validly ~~not~~withdrawn behave ~~accurate~~been oraccepted ~~complete~~for aspurchase by Purchaser in accordance with the terms of ~~any~~the ~~specified~~Offer ~~date,~~and ~~may~~payment for such Shares has been or will be ~~subject~~promptly tomade aat ~~contractual standard~~the ofOffer ~~materiality~~Price. ~~different~~Accordingly, ~~from~~a ~~those~~change ~~generally~~of ~~applicable~~control toof Orthovita’s ~~SEC~~has ~~filings~~occurred orand Purchaser has acquired control.

3Including payments made in connection with Shares validly tendered and not withdrawn in the Offer (which includes Shares subject to guarantees of delivery) and the Merger, the total amount of consideration payable in connection with the change of control transaction was $304,546,475. All amounts paid by Purchaser in connection with the Offer and the Merger were from Parent’s cash on hand.

~~may~~Pursuant ~~have~~to ~~been~~the ~~used~~terms ~~for~~and ~~purposes~~conditions of ~~allocating~~the ~~risk~~Merger ~~among Orthovita~~Agreement, the directors of Purchaser ~~and~~immediately ~~Parent~~prior ~~rather~~to ~~than~~the ~~establishing~~Effective ~~matters~~Time asshall ~~facts.~~be the ~~Investors~~directors ~~should~~of ~~not~~the ~~rely~~Company onuntil the ~~representations,~~earlier ~~warranties and~~of ~~covenants~~their resignation or ~~any~~removal ~~description~~or ~~thereof~~until astheir ~~characterizations~~respective ofsuccessors are duly elected and qualified, as the ~~actual~~case ~~state~~may ofbe. ~~facts~~A description of ~~Orthovita,~~the ~~Parent,~~changes ~~Purchaser~~to orthe ~~any~~membership of the ~~respective~~Company’s ~~subsidiaries~~board orof directors ~~affiliates~~is set forth in Item 5.02 below.

The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, which is filed as Exhibit 2.1 hereto and incorporated herein by reference.

Tender and Voting Agreements

In connection with the Merger Agreement, Parent and Purchaser have entered into Tender and Voting Agreements with each of Orthovita’s directors and executive officers and with Essex Woodlands Health Ventures Fund VII, L.P.(“Essex Woodlands”) pursuant to which, among other things, such shareholders have agreed to tender (and deliver any certificates evidencing) all of their shares of Orthovita common stock (including shares acquired upon the exercise of options), representing approximately 14.5% of the fully diluted shares of Orthovita common stock, as well as any additional shares acquired after the date of Tender and Voting Agreement, in the Offer promptly following the commencement of the Offer, and in any event no later than 10 business days following the commencement of the Offer. The foregoing description of the Tender and Voting Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Tender and Voting Agreement, which is filed as Exhibit 99.1 hereto, and Essex Woodlands’ Tender and Voting Agreement which is filed as Exhibit 99.2 hereto, each incorporated herein by reference.

Financial Advisor and Legal Advisor

J.P. Morgan Securities LLC served as exclusive financial advisor to Orthovita and delivered a fairness opinion to the Orthovita board of directors on the transaction. Duane Morris LLP served as legal counsel to Orthovita on the transaction.

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

OnIn ~~May~~accordance with the Merger Agreement, on June 1527, 2011, ~~Orthovita’s~~each ~~board~~ of ~~directors~~Scott Barry, ~~upon~~Morris ~~recommendation~~Cheston, ofJr., Antony ~~the~~Koblish, ~~compensation~~Mary ~~committee~~Paetzold, ofPaul ~~the~~Thomas, ~~board~~William ofE. ~~directors~~Tidmore, ~~approved~~Jr. and Paul T. Touhey, Jr. resigned as directors of the ~~payment~~Company as of athe ~~$500,000~~Effective ~~bonus~~Time. Pursuant to ~~Antony~~the ~~Koblish~~Merger Agreement, ~~Orthovita’s~~ ~~President~~as of the Effective Time, Mary Anne McDonald and ~~Chief~~Tony ~~Executive~~M. McKinney ~~Officer~~(collectively, ~~contingent~~the ~~upon~~“New Directors”), the ~~acceptance~~directors of ~~Shares~~Purchaser byimmediately ~~Purchaser~~prior into the ~~Offer~~Effective Time, became directors of the Company.

~~Item~~In accordance with the Merger Agreement, on June 827, 2011, each of Antony Koblish, Nancy C.01 Broadbent, Maarten Persenaire, M.D. and Christopher H. Smith ceased to serve as officers of ~~Other~~the ~~Events~~Company. As of the Effective Time, Kevin A. Lobo and Wayne D. Dahlberg (collectively, the “New Officers”), officers of Purchaser immediately prior to the Effective Time, became the Company’s President and Vice President, Finance, respectively.

~~On May 16, 2011, Orthovita issued a press release announcing the execution of the Merger Agreement, a copy of which is filed as Exhibit 99.~~3 ~~hereto and incorporated herein by reference.~~

4Kevin A. Lobo, age 46, is currently Group President, Orthopaedics, of Parent, a leading medical technology company, and was appointed to that position in April 2011. Prior to joining Parent, he served as Worldwide President of Ethicon Endo-Surgery, a division of Johnson & Johnson, a manufacturer of health care products, from June 2009 to April 2011, as President of Ethicon Endo-Surgery from July 2006 to May 2009 and President of Johnson & Johnson Medical Products from October 2005 to July 2006. He also served as Vice President, Finance, for the McNeil Consumer and Specialty Pharmaceuticals business and served as the General Manager for the McNeil Consumer Healthcare business in Canada. Prior to joining Johnson & Johnson, Kevin served in general management and financial and information technology leadership roles for eight years at Rhodia, the chemical spin-off from Rhone-Poulenc, a French chemical and pharmaceutical company.

~~Notice~~Wayne D. Dahlberg, age 51, is currently Vice President, Chief Financial Officer and Compliance Officer of Parent’s Orthopaedics division, and was appointed to ~~Investors~~that position in 2009. He had previously been the Vice President, Finance and Compliance since 2008 and Vice President, Finance since 1999 at the Orthopaedics division.

~~The~~There ~~Offer~~are ~~for~~no ~~Shares~~family ofrelationships ~~Orthovita~~between ~~referred~~any toof inthe ~~this~~New ~~Current~~Officers ~~Report~~and onthe ~~Form~~Company’s ~~8-K~~directors ~~has~~or ~~not~~executive ~~yet~~officers, ~~commenced. This report~~ and the ~~description~~Company has ~~contained~~not ~~herein~~entered isinto ~~neither~~any antransactions ~~offer~~with toany ~~purchase nor a solicitation~~ of anthe ~~offer~~New toOfficers ~~sell~~or ~~any securities. The solicitation and~~ the ~~offer~~New toDirectors ~~buy~~that ~~Shares~~are ~~will~~reportable ~~be made~~ pursuant to anItem 404(a) ~~offer~~of toRegulation ~~purchase and related materials that Purchaser intends to file with the SEC~~S-K.

AtItem the time the Offer is commenced, Purchaser will file a Tender Offer Statement on Schedule TO (including an offer to purchase, letter of transmittal and related tender offer documents) with the SEC and Orthovita will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the Offer5.03 ~~Shareholders~~Amendments ~~of Orthovita are strongly advised~~ to ~~read~~Articles the Tender Offer Statement and the related Solicitation/Recommendation Statement because they will contain important information that shareholders should consider before making any decision regarding the Offer. The Tender Offer Statement and certain other offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all shareholders of ~~Orthovita~~Incorporation ~~at no expense to them. These documents will be available at no charge on the SEC’s web site at http://www.sec.gov. Investors and shareholders may also obtain, at no charge, the documents filed with~~ or ~~furnished~~By-Laws; toChange ~~the~~in ~~SEC~~Fiscal ~~by Orthovita at http://www~~Year.~~orthovita.com.~~

~~Forward-Looking~~Effective ~~Statements~~June 27, 2011, in connection with the Merger, (i) the Company’s articles of incorporation were amended and restated (the “Amended and Restated Articles of Incorporation”), and (ii) the Company’s bylaws were amended to be in substantially the form of Purchaser’s bylaws. Following the Effective Time, the Company’s bylaws were again amended and restated, effective as of June 28, 2011 (the “Second Amended and Restated Bylaws”).

~~This~~The ~~report~~Amended ~~contains~~and ~~forward-looking~~Restated ~~statements that~~Articles ~~are not historical facts. Orthovita has identified some~~ of ~~these forward-looking statements with words like “believe,” “may,” “could,” “would,” “might,” “possible,”~~Incorporation “potential,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “estimate,” “approximate” “outlook” or “continue” or the negative of these words, other terms of similar meaning or the use of future dates. Forward-looking statements in this report include without limitation statements regarding the anticipated timing of filings and ~~approvals relating to~~ the ~~transaction; statements~~Second ~~regarding~~Amended the expected timing of the completion of the transaction; statements regarding the ability to complete the transaction considering the various closing conditions; any statements of expectation or belief; and ~~any~~Restated ~~statements~~Bylaws ~~of assumptions underlying any of the foregoing. Investors and security holders~~ are ~~cautioned~~attached ~~not~~hereto toas ~~place~~Exhibits ~~undue reliance on these forward-looking statements~~3.1 ~~Actual results could differ materially from those currently anticipated due to a number of risks~~ and ~~uncertainties~~3. Risks and uncertainties that could cause results to differ from expectations include: uncertainties as to the timing of the Offer and Merger; uncertainties as to how many of Orthovita’s shareholders will tender their Shares in the Offer; the risk that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived2, ~~including that a governmental entity may prohibit~~respectively, delay or refuse to grant approval for the consummation of the transaction; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, customers, vendors and ~~other~~are ~~business~~incorporated ~~partners;~~herein ~~the~~by ~~risk~~reference. that shareholder litigation in connection with the Offer and Merger may result in significant costs of defense, indemnification and liability; other business effects, including the effects of industry, economic or political conditions outside of Orthovita’s control; transaction costs; actual or contingent liabilities; and other risks and uncertainties discussed in Orthovita’s filings with the

5The foregoing descriptions of the Merger Agreement do not purport to be complete and are qualified in their entirety by reference to the Merger Agreement, which is incorporated into this report by reference to Exhibit 2.1 to the Company’s Current Report filed with the SEC on May 16, 2011.

SEC, including the “Risk Factors” sections of Orthovita’s most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q, as well as the tender offer documents to be filed by Purchaser and the Solicitation/Recommendation Statement to be filed by Orthovita. Copies of Orthovita’s filings with the SEC may be obtained at the “Investors” section of Orthovita’s website at http://www.orthovita.com. Orthovita does not undertake any obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as expressly required by law. All forward-looking statements in this report are qualified in their entirety by this cautionary statement. Orthovita notes that forward-looking statements made in connection with the Offer are not subject to the safe harbors created by the Private Securities Litigation Reform Act of 1995, as amended. Orthovita is not waiving any other defenses that may be available under applicable law.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
2.1		Agreement and Plan of Merger, dated as of May 16, 2011, among Stryker Corporation, Owl Acquisition Corporation and Orthovita, Inc.* (filed herewith)
3.1		Amended and Restated Articles of Incorporation of Orthovita, Inc.
10.1		Amendment No. 1 to Warrant, dated May 16, 2011, by Orthovita, Inc. and LB I Group, Inc. (filed herewith)
3.2		Second Amended and Restated Bylaws of Orthovita, Inc.
99.1		Form of Tender and Voting Agreement, dated as of May 16, 2011, between Purchaser and each of the directors and executive officers of Orthovita, Inc. and Essex Woodlands Health Ventures Fund VII, L.P. (filed herewith)
99.2		Tender and Voting Agreement, dated as of May 16, 2011, between Purchaser and Essex Woodlands Health Ventures Fund VII, L.P. (filed herewith)
99.3		Press Release dated May 16, 2011 (filed herewith)

*4 The schedules to the Merger Agreement have been omitted from this report pursuant to Item 601(b)(2) of Regulation S-K. Orthovita will furnish copies of any such schedules to the U.S. Securities and Exchange Commission upon request.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~ORTHOVITA, INC. By~~Date: ~~/s/~~July ~~CHRISTINE~~1, J.2011 ~~ARASIN Christine J. Arasin Vice President and General Counsel~~

~~Dated~~ORTHOVITA, INC. By: ~~May 16,~~/s/ ~~2011~~Kevin A. Lobo

7Name: Kevin A. Lobo Title: President

Filing Compare · ORTHOVITA INC